LLY

1,066.82

+2.48%↑

JNJ

234.57

+1.33%↑

ABBV

216.12

+0.45%↑

UNH

388.17

+1.5%↑

AZN

187.25

-1.32%↓

LLY

1,066.82

+2.48%↑

JNJ

234.57

+1.33%↑

ABBV

216.12

+0.45%↑

UNH

388.17

+1.5%↑

AZN

187.25

-1.32%↓

LLY

1,066.82

+2.48%↑

JNJ

234.57

+1.33%↑

ABBV

216.12

+0.45%↑

UNH

388.17

+1.5%↑

AZN

187.25

-1.32%↓

LLY

1,066.82

+2.48%↑

JNJ

234.57

+1.33%↑

ABBV

216.12

+0.45%↑

UNH

388.17

+1.5%↑

AZN

187.25

-1.32%↓

LLY

1,066.82

+2.48%↑

JNJ

234.57

+1.33%↑

ABBV

216.12

+0.45%↑

UNH

388.17

+1.5%↑

AZN

187.25

-1.32%↓

Home・Elenco Azioni・Arcutis Biotherapeutics Inc

Arcutis Biotherapeutics Inc

Chiusa

SettoreSettore sanitario

20.78 -0.95

Acquista Vendi

Panoramica

Variazione del prezzo dell'azione

24h

Corrente

Minimo

20.6

Massimo

21.32

Metriche Chiave
By Trading Economics
Entrata	-29M -11M
Vendite	-24M 105M
EPS	-0.09
Margine di Profitto	-10.717
Dipendenti	354
EBITDA	-31M -8.5M

Raccomandazioni
By TipRanks
Raccomandazioni	Fortemente da comprare
Previsioni per 12 mesi	+69.17% upside

Dividendi
By Dow Jones
Utili prossimi	5 ago 2026

Statistiche di mercato
By TradingEconomics
Capitalizzazione di Mercato	-433M 2.5B
Apertura precedente	21.73
Chiusura precedente	20.78

Punteggio Tecnico

By Trading Central

Fiducia

Strong Bearish Evidence

12.42 / 14.93 Supporto e resistenza

Arcutis Biotherapeutics Inc Grafico

Le prestazioni passate non sono un indicatore affidabile dei risultati futuri.

Notizie correlate

22 mag 2026, 16:33 UTC

Utili

I principali Market Mover

Webull Shares Slide on 1Q Loss, Soaring Costs

22 mag 2026, 21:10 UTC

Utili

These Stocks Are Today's Movers: Dell, Apple, IBM, Estée Lauder, Futu, Rocket Lab, Workday, and More -- Barrons.com

22 mag 2026, 20:50 UTC

Discorsi di Mercato

Tech, Media & Telecom Roundup: Market Talk

22 mag 2026, 20:50 UTC

Discorsi di Mercato

Acquisizioni, Fusioni, Takeovers

Financial Services Roundup: Market Talk

22 mag 2026, 20:50 UTC

Discorsi di Mercato

Auto & Transport Roundup: Market Talk

22 mag 2026, 20:50 UTC

Discorsi di Mercato

Basic Materials Roundup: Market Talk

22 mag 2026, 19:47 UTC

Utili

Nvidia Has a Plan to Get the Stock Moving Again -- Barrons.com

22 mag 2026, 19:17 UTC

Discorsi di Mercato

U.S. Natural Gas Retreats As Weather Outlook Cools -- Market Talk

22 mag 2026, 19:10 UTC

Discorsi di Mercato

Oil Futures Edge Up Ahead of U.S. Long Weekend -- Market Talk

22 mag 2026, 18:54 UTC

Discorsi di Mercato

Global Equities Roundup: Market Talk

22 mag 2026, 18:54 UTC

Discorsi di Mercato

Kroger Seen Narrowing Pricing Gap Versus Walmart -- Market Talk

22 mag 2026, 18:38 UTC

Discorsi di Mercato

Canada's Population Slowdown Hits Demand for Consumer Companies -- Market Talk

22 mag 2026, 18:35 UTC

Acquisizioni, Fusioni, Takeovers

IMAX Might Be Exploring a Sale. Who Could Be Buying. -- Barrons.com

22 mag 2026, 18:09 UTC

Discorsi di Mercato

Centralized Crypto Lending Slows in 1Q -- Market Talk

22 mag 2026, 17:58 UTC

Discorsi di Mercato

U.S. Oil Rig Count Shows Signs of Picking Up -- Market Talk

22 mag 2026, 17:54 UTC

Discorsi di Mercato

Market Talk Roundup: Latest on U.S. Politics

22 mag 2026, 17:54 UTC

Discorsi di Mercato

Global Forex and Fixed Income Roundup: Market Talk

22 mag 2026, 17:54 UTC

Discorsi di Mercato

Canada Minister May Be Distancing From Online-Streaming Order -- Market Talk

22 mag 2026, 17:03 UTC

Discorsi di Mercato

Canada Spending Obligations on Streamers Is More Severe Beneath Surface -- Market Talk

22 mag 2026, 16:54 UTC

Discorsi di Mercato

Crypto Spot Volumes Fall 14% in April -- Market Talk

22 mag 2026, 16:20 UTC

Discorsi di Mercato

Acquisizioni, Fusioni, Takeovers

Financial Services Roundup: Market Talk

22 mag 2026, 16:20 UTC

Discorsi di Mercato

Auto & Transport Roundup: Market Talk

22 mag 2026, 16:20 UTC

Discorsi di Mercato

Energy & Utilities Roundup: Market Talk

22 mag 2026, 16:20 UTC

Discorsi di Mercato

Basic Materials Roundup: Market Talk

22 mag 2026, 16:16 UTC

Discorsi di Mercato

TSX Growth Driven Almost Entirely by Materials Sector -- Market Talk

22 mag 2026, 16:15 UTC

Discorsi di Mercato

Global Commodities Roundup: Market Talk

22 mag 2026, 15:55 UTC

Discorsi di Mercato

Trump Admin Grants Reinforce IBM's Quantum Computing Leadership -- Market Talk

22 mag 2026, 15:42 UTC

Discorsi di Mercato

Global Forex and Fixed Income Roundup: Market Talk

22 mag 2026, 15:42 UTC

Discorsi di Mercato

Oil Continues as Leading Indicator for All Markets -- Market Talk

22 mag 2026, 15:35 UTC

Discorsi di Mercato

Gas Prices May Limit Spread of Inflationary Pressures in Canada -- Market Talk

Confronto tra pari

Modifica del prezzo

Arcutis Biotherapeutics Inc Previsione

Obiettivo di Prezzo

By TipRanks

69.17% in crescita

Previsioni per 12 mesi

Media 34.63 USD 69.17%

Alto 36 USD

Basso 33 USD

Basato su 8 analisti di Wall Street che offrono Obiettivi di Prezzo a 12 mesi per Arcutis Biotherapeutics Inc - Dist negli ultimi 3 mesi.

Consenso sulla valutazione

By TipRanks

Fortemente da comprare

8 ratings

Acquista

Mantieni

Vendi

Basato sugli analisti di 8 che hanno fornito valutazioni azionarie a Arcutis Biotherapeutics Inc - Dist negli ultimi 3 mesi.

Punteggio Tecnico

By Trading Central

12.42 / 14.93Supporto e resistenza

Recent bearish events outweigh bullish events.

There is one bullish event.

Notizie finanziarie

Spese di vendita e di amministrazione

Spese operative

Utile prima delle imposte

Vendite

Costo delle vendite

Utile lordo sulle vendite

Interessi passivi sul debito

EBITDA

Utile operativo

Chi Siamo Arcutis Biotherapeutics Inc

Arcutis Biotherapeutics, Inc., a biopharmaceutical company, focuses on developing and commercializing treatments for dermatological diseases. Its lead product candidate is ARQ-151, a topical roflumilast cream that has completed Phase III clinical trials for the treatment of plaque psoriasis and atopic dermatitis. The company is also developing ARQ-154, a topical ZORYVE for the treatment of scalp and body psoriasis and seborrheic dermatitis; ARQ-252, a selective topical janus kinase type 1 inhibitor for hand eczema and vitiligo; ARQ-255, a topical JAK1 inhibitor for alopecia areata; and ARQ-234, a CD200R fusion protein for the treatment of moderate-to-severe atopic dermatitis. The company was formerly known as Arcutis, Inc. and changed its name to Arcutis Biotherapeutics, Inc. in October 2019. Arcutis Biotherapeutics, Inc. was incorporated in 2016 and is headquartered in Westlake Village, California.